Bio-Thera Solutions, in collaboration with Hikma Pharmaceuticals, has announced the FDA approval of STARJEMZA® (ustekinumab-hmny) Injection. This approval represents Bio-Thera’s third biosimilar to gain regulatory clearance, highlighting the company’s growing influence in the biopharmaceutical industry.
Strategic Partnership Enhances Market Reach
The partnership, established in August 2021, assigns Bio-Thera the responsibility for developing and manufacturing STARJEMZA®, while Hikma takes charge of its commercialization in the United States. Dr. Bill Larkins, President of Hikma Injectables, emphasized the strategic advantage this collaboration provides in entering the competitive U.S. biosimilar market, leveraging Hikma’s strong presence in sterile injectable medicines.
Robust Clinical Validation Ensures Efficacy
STARJEMZA® underwent comprehensive analytical, non-clinical, and clinical evaluations to demonstrate its biosimilarity to Stelara®. The FDA’s approval was based on data showing comparable structural, physicochemical, and biological properties. Clinical trials, including randomized double-blind studies, confirmed STARJEMZA®’s similar efficacy, safety, and immunogenicity profiles in treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Inferences:
- STARJEMZA® provides a more affordable treatment option, potentially increasing patient accessibility.
- The collaboration leverages Hikma’s established U.S. distribution channels for a successful market entry.
- Approval may encourage further biosimilar developments in the market.
The introduction of STARJEMZA® is poised to enhance patient access to essential therapies for chronic inflammatory conditions. By offering a biosimilar alternative to Stelara®, Bio-Thera and Hikma aim to reduce treatment costs and alleviate the financial burden on healthcare systems.
This milestone not only strengthens Bio-Thera’s position as a leading biosimilar developer but also underscores Hikma Pharmaceuticals’ commitment to expanding its biosimilar portfolio. The combined expertise of both companies ensures that STARJEMZA® meets the high standards required for effective and safe patient care.
As the biosimilar market continues to evolve, the successful launch of STARJEMZA® sets a precedent for future collaborations and product approvals. Patients and healthcare providers can look forward to more innovative and cost-effective treatment options emerging from such strategic partnerships.
<a href="https://www.hikma.com/news/bio-thera-solutions-and-hikma-pharmaceuticals-announce-fda-approval-of-starjemza-ustekinumab-hmny-injection-a-biosimilar-referencing-stelara-ustekinumab-injection/”>Source
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
